Articles related to ALZHEIMER'S/DEMENTIA

Drawing from animal evidence that aging and metabolic dysfunction result in depletion of NAD+ within neurons, B3 supplementation of 500mg BID for 6 weeks was studied as a means of increasing available NAD+. As published in Nature, a small but significant increase in NAD+ available to neurons was seen with B3 supplementation.

Two-hundred sixteen (216) people with mild-to-moderate disease were treated with 100 mg simufilam tablets twice daily for 12 months. ADAS-Cog-11 score showed a “highly desirable” overall minimal decline in cognitive ability after one year. Simufilam is an oral small molecule designed to to prevent beta and tau amyloid clumping by correctong an altered form of filamin A.

Top-line data from an open-label Phase 2 study of 216 people with mild-to-moderate Alzheimer’s disease treated with simufilam tablets at 100 mg twice daily for a year revealed a minimal decline in cognitive ability overall, as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-11). Simufilam was found to be safe and well tolerated, and it alleviated depression and dementia-related behaviors in patients, which were two exploratory trial goals.

These researchers explain that long-term high fructose intake sustains our primal foraging response, which causes the brain to constantly seek high fat, sugary, and salty foods. When constantly fed, this response can ultimately lead to neural inflammation, creating the conditions that lead to Alzheimer’s.

Plasma P-tau217 significantly predicted longitudinal cognitive decline in both cohorts in this prognostic study of data from two preclinical AD cohort studies involving 171 cognitively unimpaired individuals with cerebrospinal fluid or positron emission tomographic measures of β-amyloid positivity. These findings imply that plasma P-tau217 could be used in clinical trials of novel disease-modifying treatments as a supplement to CSF or PET for participant selection.

Only 5 to 10 percent of Alzheimer’s cases are diagnosed in people under the age of 65. However, a BCBS report shows that from 2013 to 2017, there was a 200 percent increase in Alzheimer’s diagnoses in people ages 30 to 64. This case reports the youngest patient yet diagnosed with Alzheimer’s disease.